Zephyr AI Appoints Dr. Lisa Eli as Chief Scientific Officer

Zephyr AI, a company focused on using artificial intelligence (AI) for drug development, has appointed Dr. Lisa Eli as its new Chief Scientific Officer. This move places a seasoned oncology expert at the forefront of the company's efforts to advance precision medicine.

Dr. Eli brings more than 20 years of experience in translational medicine and precision oncology. Translational medicine focuses on applying scientific discoveries to improve human health. Her background includes leading integrated biomarker and diagnostic strategies across various clinical trial phases. This work has supported patient selection and regulatory approvals for cancer treatments.

At Zephyr AI, Dr. Eli will apply her expertise to develop targeted therapies, leveraging the company's AI capabilities. This involves accelerating AI-powered, biomarker-driven diagnostic and clinical development. Dr. Eli expressed enthusiasm for her new role, emphasizing AI's potential when combined with real-world data. She highlights this combination as a method to accelerate cancer therapy development and improve patient care.

Zephyr AI utilizes AI-enabled software and large real-world datasets to convert complex clinical and biological information into actionable insights. The company aims to advance therapeutic development, refine patient stratification, and drive diagnostic innovation. Dr. Eli's appointment reinforces this strategic direction.

Her experience, including leading biomarker-driven patient stratification and clinical development strategies at her own consultancy and senior roles at Puma Biotechnology and Monogram Biosciences, aligns with Zephyr AI's mission. She contributed to developments such as the SUMMIT basket trial for HER2 mutations, which targets specific genetic changes in tumors.

This appointment signals Zephyr AI's continued investment in leadership with deep scientific expertise. The goal is to enhance its ability to apply proprietary data and machine learning to develop new drugs more efficiently. Watch for how Zephyr AI's pipeline evolves with Dr. Eli's scientific leadership and her strategies for integrating AI with precision oncology.